A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia

Gynecologic Oncology

Volumn 125, Issue 1, 2012, Pages 136-140

  MacKay, H J ^a   Buckanovich, R J ^b   Hirte, H ^c   Correa, R ^a   Hoskins, P ^d   Biagi, J ^e   Martin, L P ^f   Fleming, G F ^g   Morgan, R ^h   Wang, L ^a   Polintan, R ^a   Oza, A M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF MICHIGAN   (United States)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e Cancer Centre of Southeastern Ontario   (Canada)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aflibercept (VEGF Trap); Carcinosarcoma; Phase II; Uterine leiomyosarcoma

Indexed keywords

AFLIBERCEPT;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER PATIENT; CARCINOSARCOMA; COHORT ANALYSIS; CONSTIPATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; LEIOMYOSARCOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CARCINOMA; OVARY METASTASIS; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; UNITED STATES; UTERINE TUBE CARCINOMA; UTERUS CARCINOMA; UTERUS SARCOMA; VOICE CHANGE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CALIFORNIA; CARCINOSARCOMA; CHICAGO; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEIOMYOSARCOMA; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84858339404     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.042     Document Type: Article

References (35)

1. S. Kanjeekal, A. Chambers, and M. Fung Kee Fung Systemic therapy for advanced uterine sarcoma: a systematic review of the literature Gynecol Oncol 97 2005 624 637 (Pubitemid 40614914)
2. M.A. Clark, C. Fisher, and I. Judson Soft-tissue sarcomas in adults N Engl J Med 353 2005 701 711 (Pubitemid 41175678)
3. A. Gadducci, E. Sartori, and F. Landoni The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases Eur J Gynaecol Oncol 23 2002 295 299 (Pubitemid 34948043)
4. W.G. McCluggage Uterine carcinosarcomas (malignant mixed Mullarian tumors) are metaplastic carcinomas Int J Gynecol Cancer 12 2002 687 690 (Pubitemid 35388035)
5. G. Sutton, V.L. Brunetto, and L. Kilgore A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study Gynecol Oncol 79 2000 147 153
6. H. Homesley, V. Filiaci, and M. Markman Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: A Gynecologic Oncology Group study J Clin Oncol 25 2007 526 531 (Pubitemid 350002959)
7. M.A. Powell, V.L. Filiaci, and P.G. Rose A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study J Clin Oncol 28 2010 2727 2731
8. G.P. Sutton, J.A. Blessing, and R.J. Barrett Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study Am J Obstet Gynecol 166 1992 556 559
9. R.E. Slayton, J.A. Blessing, and C. Angel Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study Cancer Treat Rep 71 1987 1303 1304
10. G. Sutton, J. Blessing, and P. Hanjani Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study Gynecol Oncol 96 2005 749 752 (Pubitemid 40255496)
11. R. Sanfilippo, F. Grosso, and R.L. Jones Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers Gynecol Oncol 123 3 2011 Dec 553 556 [Electronic publication ahead of print 2011 Sep 13. PMID: 21917307]
12. I. Judson, J. Blay, and S. Chawla Trabectedin in the treatment of advanced uterine leiomyosarcomas: results of a pooled analysis of five single-agent phase II studies using the recommended dose J Clin Oncol 28 2010 15s [suppl; abstr 10028]
13. M.L. Hensley, J.A. Blessing, R. Mannel, and P.G. Rose Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial Gynecol Oncol 109 2008 329 334 (Pubitemid 351754961)
14. M.L. Hensley, J.A. Blessing, K. DeGeest, and O. Abulafia Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Gynecol Oncol 109 2008 323 328
15. A. Mitsuhashi, K. Suzuka, and K. Yamazawa Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma Cancer 103 2005 724 730 (Pubitemid 40216400)
16. A.A. Kamat, W.M. Merritt, and D. Coffey Clinical and biological significance of vascular endothelial growth factor in endometrial cancer Clin Cancer Res 13 2007 7487 7495
17. L.M. Ramondetta, T.W. Burke, and A. Jhingran A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets Gynecol Oncol 90 2003 529 536
18. S. Arita, F. Kikkawa, and H. Kajiyama Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma Int J Gynecol Cancer 15 2005 329 336 (Pubitemid 40396974)
19. E.E. Pakos, A.C. Goussia, and P.G. Tsekeris Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas Anticancer Res 25 2005 3591 3596 (Pubitemid 41105246)
20. D.S. McMeekin, M.W. Sill, M. Kathleen, K.M. Darcy, and D.J. Stearns-Kurosawa A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study Gynecol Oncol 106 2007 596 603 (Pubitemid 47304476)
21. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398 (Pubitemid 34920936)
22. J. Dupont, M.L. Rothenberg, and D.R. Spriggs Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors Proc Am Soc Clin Oncol 23 2005 199s
23. P. Therasse, S. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
24. M. Van Glabbeke, J. Verweij, and I. Judson Progression-free rate as the principal end-point for phase II trials in soft tissue sarcoma Eur J Cancer 38 2002 543 549 (Pubitemid 34185394)
25. R. Koivisto-Korander, R. Butzow, A.M. Koivisto, and A. Leminen Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers Tumour Biol 32 3 2011 451 459
26. M.L. Hensley, M.W. Sill, and D.R. Scribner Jr. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Gynecol Oncol 115 2009 460 465
27. K.Y. Look, A. Sandler, and J.A. Blessing Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study Gynecol Oncol 92 2004 644 647 (Pubitemid 38183157)
28. S. Sleijfer, I. Ray-Coquard, and Z. Papai Pazopanib, a multikinase angiogenesis inhibitor in patients with relapsed of refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) J Clin Oncol 27 2009 3126 3132
29. H.S. Nimeiri, A.M. Oza, and R.J. Morgan A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 117 2010 37 40
30. R.A. Burger, M.W. Sill, and B.J. Monk Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171 (Pubitemid 350237599)
31. W.K. Huh, M.W. Sill, and K.M. Darcy Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus Gynecol Oncol 117 2010 248 254
32. B.E. Miller, J.A. Blessing, F.B. Stehman, and M.S. Shahin A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study Gynecol Oncol 118 2010 139 144
33. G.P. Sutton, J.A. Blessing, H.D. Homesley, and J.H. Malfetano A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study Gynecol Oncol 53 1994 24 26
34. N.B. Leighl, E. Luis, L.E. Raez, and B. Besse A multicenter, phase 2 study of vascular endothelial growth factor Trap (aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung J Thorac Oncol 10 2010 1054 1059
35. P. Twardowski, W.M. Stadler, and P. Frankel Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial Urology 76 2010 923 926